Anti-Heat Shock Protein 70 Antibodies in Meniere's Disease

Objectives To determine the prevalence of anti–heat shock protein 70 (anti‐HSP70) antibodies in patients with Meniere's disease and healthy subjects and to probe the relationship between antibody status and clinical features of Meniere's disease. Study Design Prospective cohort study of consecutive consenting patients with Meniere's disease. Methods Serum samples were obtained prospectively from 134 patients with Meniere's disease and 124 blood donors. Serial samples were taken at 3‐month intervals in 38 of 134 patients with Meniere's disease. Demographic data and clinical characterization of vestibular and auditory status were acquired with each sample. Serum was assayed for anti‐HSP70 antibodies by Western blot using bovine renal extract, recombinant bovine HSP70, and recombinant human HSP70 antigens. Results Immunoreactivity against bovine renal extract HSP70 was found in 38% of patients with Meniere's disease, compared with 25% of blood donors (P < .04). Reactivity with recombinant antigens was not significantly different between patients with Meniere's disease and healthy control subjects. Patients with Meniere's disease who reacted with all three antigens were more likely to have simultaneously active hearing and balance symptoms (P = .03). Neither univariate nor multivariate statistical analysis established any other association between serological findings and clinical features of Meniere's disease. Tests performed on serial samples of patients with Meniere's disease also showed no association of positive or negative test results with changes in clinical course. Conclusions Because of the high prevalence of anti‐HSP70 antibodies in healthy subjects and the very limited association of anti‐HSP70 antibody status with clinical features or course of Meniere's disease, we conclude that, at present, the detection of anti‐HSP70 antibodies by Western blotting offers little clinically useful information in Meniere's disease.